_id
69147d2eccc777a4e85d9172
Ticker
MTSR
Name
Metsera, Inc. Common Stock
Exchange
NASDAQ
Address
3 World Trade Center, New York, NY, United States, 10007
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://metsera.com
Description
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York.
Last Close
70.75
Volume
3185766
Current Price
70.5
Change
-0.35335689045936397
Last Updated
2025-11-12T12:27:25.629Z
Image
data:image/webp;base64,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
Ipo Date
2025-01-31T00:00:00.000Z
Market Cap
4123973376
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.49765055555555565
Sentiment Sources
180
Rating
5
Target Price
-
Strong Buy
4
Buy
0
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-06-30
Revenue
0
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
71123000
Operating Income
-71123000
Interest Expense
39000
Pretax Income
-68715000
Net Income
-68715000
Eps
-0.6551773455377574
Dividends Per Share
-
Shares Outstanding
104880000
Income Tax Expense
-
EBITDA
-68669000
Total Other Income Expense Net
-
Cash
530919000
Short Term Investments
-
Receivables
-
Inventories
-
Total Current Assets
538076000
Property Plant Equipment
1290000
Total Assets
639660000
Payables
22912000
Short Term Debt
740000
Long Term Debt
-
Total Liabilities
190428000
Equity
449232000
Depreciation
7000
Change In Working Capital
13392000
Cash From Operations
-58964000
Capital Expenditures
191000
Cash From Investing
-191000
Cash From Financing
-1512000
Net Change In Cash
-57416000
PE
-
PB
16.459290522491717
ROE
-15.296105353136019
ROA
-10.742425663633806
FCF
-59155000
Fcf Percent
-
Piotroski FScore
1
Health Score
35
Deep Value Investing Score
3.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2
Net Net Investing Score
2.5
Quality Investing Score
2.5
Value Investing Score
3
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
71123000
Quarters > 0 > income Statement > operating Income
-71123000
Quarters > 0 > income Statement > interest Expense
39000
Quarters > 0 > income Statement > pretax Income
-68715000
Quarters > 0 > income Statement > net Income
-68715000
Quarters > 0 > income Statement > eps
-0.6551773455377574
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
104880000
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-68669000
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > balance Sheet > cash
530919000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
538076000
Quarters > 0 > balance Sheet > property Plant Equipment
1290000
Quarters > 0 > balance Sheet > total Assets
639660000
Quarters > 0 > balance Sheet > payables
22912000
Quarters > 0 > balance Sheet > short Term Debt
740000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
190428000
Quarters > 0 > balance Sheet > equity
449232000
Quarters > 0 > cash Flow > net Income
-68715000
Quarters > 0 > cash Flow > depreciation
7000
Quarters > 0 > cash Flow > change In Working Capital
13392000
Quarters > 0 > cash Flow > cash From Operations
-58964000
Quarters > 0 > cash Flow > capital Expenditures
191000
Quarters > 0 > cash Flow > cash From Investing
-191000
Quarters > 0 > cash Flow > cash From Financing
-1512000
Quarters > 0 > cash Flow > net Change In Cash
-57416000
Quarters > 0 > ratios > PE
-0.6551773455377574
Quarters > 0 > ratios > PB
16.459290522491717
Quarters > 0 > ratios > ROE
-15.296105353136019
Quarters > 0 > ratios > ROA
-10.742425663633806
Quarters > 0 > ratios > FCF
-59155000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
35
Quarters > 1 > quarter
2025-03-31
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
5000
Quarters > 1 > income Statement > gross Profit
-5000
Quarters > 1 > income Statement > operating Expenses
79808000
Quarters > 1 > income Statement > operating Income
-79808000
Quarters > 1 > income Statement > interest Expense
101000
Quarters > 1 > income Statement > pretax Income
-76588000
Quarters > 1 > income Statement > net Income
-76588000
Quarters > 1 > income Statement > eps
-1.029531011173721
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
74391154
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-76482000
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > balance Sheet > cash
588335000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
594738000
Quarters > 1 > balance Sheet > property Plant Equipment
1274000
Quarters > 1 > balance Sheet > total Assets
690695000
Quarters > 1 > balance Sheet > payables
15244000
Quarters > 1 > balance Sheet > short Term Debt
727000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
185308000
Quarters > 1 > balance Sheet > equity
505387000
Quarters > 1 > cash Flow > net Income
-76588000
Quarters > 1 > cash Flow > depreciation
5000
Quarters > 1 > cash Flow > change In Working Capital
6035000
Quarters > 1 > cash Flow > cash From Operations
-54342000
Quarters > 1 > cash Flow > capital Expenditures
7000
Quarters > 1 > cash Flow > cash From Investing
-7000
Quarters > 1 > cash Flow > cash From Financing
288559000
Quarters > 1 > cash Flow > net Change In Cash
235888000
Quarters > 1 > ratios > PE
-1.029531011173721
Quarters > 1 > ratios > PB
10.377347175530831
Quarters > 1 > ratios > ROE
-15.15432727790782
Quarters > 1 > ratios > ROA
-11.088541251927406
Quarters > 1 > ratios > FCF
-54349000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2024-12-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
7000
Quarters > 2 > income Statement > gross Profit
-7000
Quarters > 2 > income Statement > operating Expenses
64500000
Quarters > 2 > income Statement > operating Income
-64500000
Quarters > 2 > income Statement > interest Expense
4000
Quarters > 2 > income Statement > pretax Income
-61270000
Quarters > 2 > income Statement > net Income
-52871000
Quarters > 2 > income Statement > eps
-0.5131354065061
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
103035182
Quarters > 2 > income Statement > income Tax Expense
-8399000
Quarters > 2 > income Statement > EBITDA
-132576000
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > balance Sheet > cash
352447000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
359133000
Quarters > 2 > balance Sheet > property Plant Equipment
1442000
Quarters > 2 > balance Sheet > total Assets
450988000
Quarters > 2 > balance Sheet > payables
20837000
Quarters > 2 > balance Sheet > short Term Debt
9101000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
163638000
Quarters > 2 > balance Sheet > equity
287350000
Quarters > 2 > cash Flow > net Income
-52871000
Quarters > 2 > cash Flow > depreciation
7000
Quarters > 2 > cash Flow > change In Working Capital
11338000
Quarters > 2 > cash Flow > cash From Operations
-36374000
Quarters > 2 > cash Flow > capital Expenditures
1000
Quarters > 2 > cash Flow > cash From Investing
-1000
Quarters > 2 > cash Flow > cash From Financing
202162000
Quarters > 2 > cash Flow > net Change In Cash
164853000
Quarters > 2 > ratios > PE
-0.5131354065061
Quarters > 2 > ratios > PB
25.27920769444928
Quarters > 2 > ratios > ROE
-18.399512789281363
Quarters > 2 > ratios > ROA
-11.723371797032293
Quarters > 2 > ratios > FCF
-36375000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
31
Quarters > 3 > quarter
2024-09-30
Quarters > 3 > income Statement > revenue
0
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
111265000
Quarters > 3 > income Statement > operating Income
-111265000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-110038000
Quarters > 3 > income Statement > net Income
-109648000
Quarters > 3 > income Statement > eps
-1.4148616474915974
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
77497330
Quarters > 3 > income Statement > income Tax Expense
-390000
Quarters > 3 > income Statement > EBITDA
-38525000
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > balance Sheet > cash
187594000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
190988000
Quarters > 3 > balance Sheet > property Plant Equipment
64000
Quarters > 3 > balance Sheet > total Assets
287270000
Quarters > 3 > balance Sheet > payables
9858000
Quarters > 3 > balance Sheet > short Term Debt
6031000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
157481000
Quarters > 3 > balance Sheet > equity
129789000
Quarters > 3 > cash Flow > net Income
-109648000
Quarters > 3 > cash Flow > depreciation
4000
Quarters > 3 > cash Flow > change In Working Capital
6276000
Quarters > 3 > cash Flow > cash From Operations
-28299000
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
139428000
Quarters > 3 > cash Flow > net Change In Cash
111226000
Quarters > 3 > ratios > PE
-1.4148616474915974
Quarters > 3 > ratios > PB
42.09572278852599
Quarters > 3 > ratios > ROE
-84.48173574031698
Quarters > 3 > ratios > ROA
-38.16896995857555
Quarters > 3 > ratios > FCF
-28299000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
25
Valuation > metrics > PE
-0.6551773455377574
Valuation > metrics > PB
16.459290522491717
Valuation > final Score
20
Valuation > verdict
448.6% Overvalued
Profitability > metrics > ROE
-15.296105353136019
Profitability > metrics > ROA
-12.770500821445296
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.4238967838444278
Risk > metrics > Interest Coverage
-1823.6666666666667
Risk > final Score
-7235
Risk > verdict
High
Liquidity > metrics > Current Ratio
22.749704041941484
Liquidity > metrics > Quick Ratio
22.749704041941484
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
20
Prev Valuations > 1
20
Prev Valuations > 2
20
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
15
Prev Risks > 0
-3101
Prev Risks > 1
-64452
Prev Risks > 2
24
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:14:59.720Z
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AMarket Recap: Whats next for MTSR stock - Profit Target & Safe Capital Allocation Plans baoquankhu1.vn
Read more →Showing 2 of 10
(Last Updated 2025-06-30)
Rating:
STRONG BUY
$
Analyst Picks
Strong Buy
4
Buy
0
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Metsera, Inc. Common Stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.